Prescribing Information can be found at the bottom of this page.
Meet Kieran...
Kieran is a restaurant manager and a keen rugby player. When he’s not running a busy restaurant, he enjoys socialising with his rugby team after matches.
“I never used to give my psoriasis too much thought, but recently it’s got worse and I can’t ignore it anymore.”
Age
37
Occupation
Restaurant manager.
Key consideration
Experiencing adverse events with methotrexate.
Medical history
Kieran is a non-smoker and drinks occasionally. He is generally in good health with no other relevant medical history.
Kieran’s psoriasis
At aged 30, Kieran was diagnosed with plaque psoriasis, which predominantly affects his limbs.
Kieran was initially prescribed topical steroids and retinoids, but has had a loss of response after 7 years. He was recently prescribed methotrexate, but had to discontinue treatment after suffering severe headaches and shortness of breath.
Treatment options
Kieran has a high DLQI score and his psoriasis is extensive. After discontinuing methotrexate due to adverse events, Skilarence® (dimethyl fumarate) could be a suitable systemic option for Kieran under NICE guidelines.
What treatment option would you choose for this patient?
Please select one from the list
NICE treatment recommendations1
Systemic non-biological therapies should be used for people with moderate-to-severe plaque psoriasis if it cannot be controlled with topical therapy
AND
it has a significant impact on physical, psychological or social well-being
AND
any of the following apply:
Psoriasis is extensive.
For example, >10% of BSA
affected or PASI score of >10
Psoriasis is localised and
associated with significant functional impairment and/or high levels of distress (e.g. involvement at high-impact sites)
Phototherapy has been ineffective, cannot be used or has resulted in rapid relapse (>50% of baseline disease severity within 3 months)
If you have any questions, our representatives are on hand for further information about Skilarence®.
BSA, body surface area. DLQI, Dermatology Life Quality Index.
NICE, National Institute of Health and Care Excellence.
PASI, Psoriasis Area Severity Index.
Reference: 1. NICE. Psoriasis assessment and management (CG153). 2012. Available at: https://www.nice.org.uk/guidance/cg153.
Related
Have you met patients like these in your clinic?
See how Skilarence® can help more patients with psoriasis. Click on a patient to find out more.
UK-IEDMF-2100002
March 2021
“I never used to give my psoriasis too much thought, but recently it’s got worse and I can’t ignore it anymore.”
Meet Kieran...
Kieran is a restaurant manager and a keen rugby player. When he’s not running a busy restaurant, he enjoys socialising with his rugby team after matches.
Age: 37
Occupation: Restaurant manager.
Key consideration: Experiencing adverse events with methotrexate.
Kieran’s psoriasis
At aged 30, Kieran was diagnosed with plaque psoriasis, which predominantly affects his limbs.
Kieran was initially prescribed topical steroids and retinoids, but has had a loss of response after 7 years. He was recently prescribed methotrexate, but had to discontinue treatment after suffering severe headaches and shortness of breath.
Medical history
Kieran is a non-smoker and drinks occasionally. He is generally in good health with no other relevant medical history.
Treatment options
Kieran has a high DLQI score and his psoriasis is extensive. After discontinuing methotrexate due to adverse events, Skilarence® could be a suitable systemic option for Kieran under NICE guidelines.